Metronomic chemotherapy (MCT) involves the chronic administration of doses of chemotherapy drugs that are below the maximum tolerated dose (MTD), at frequent and regular intervals, without extended rest periods [1]. It aims to achieve a balance between efficacy in tumor killing and lack of toxicity. The inhibition of angiogenesis would explain its therapeutic effect [2, 3].
We have demonstrated the antitumor efficacy of MCT with cyclophosphamide (Cy) as a single drug [4] and in combination with celecoxib on mice mammary adenocarcinomas (MA) [5]. Considering the high incidence of mammary tumors in humans, in this study, we analyze the therapeutic efficacy, toxicity and mechanism/s of action of MCT combining Cy and doxorubicin (Dox), in mouse MA tumor-models.